Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation ( Findings from the ASSERT Trial Presente...)

Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation

Findings from the ASSERT Trial Presented at EULAR

BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ -- Data presented today at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology showed that patients with ankylosing spondylitis (AS) who received REMICADE(R) (infliximab) over two years experienced significant improvement in spinal mobility. In addition, REMICADE-treated patients showed sustained reductions in spinal inflammation through two years as detected by magnetic resonance imaging (MRI).

The recommended dose of REMICADE in AS is 5 mg/kg given as an IV induction regimen at 0, 2 and 6 weeks followed by a 5 mg/kg maintenance regimen every 6 weeks in the United States or every 6-8 weeks in the European Union.

AS is a progressive rheumatic disease that leads to inflammation of the back, resulting in pain, stiffness and reduced mobility, which in advanced cases can result in fusion of the vertebrae of the spine ('ankylosis'). Data collected from 279 patients with AS as part of the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) trial were analyzed to determine the long-term effect of REMICADE on spinal mobility. The double-blind extension of this 24-week placebo-controlled study utilized the Bath Ankylosing Spondylitis Metrology Index (BASMI) and chest expansion measurements to assess range of motion in patients with AS.

Patients in ASSERT were treated and assessed at six week intervals through week 102. According to the findings, compared with placebo group (N=78), at week 24 the REMICADE-treated patients (N=201) had a greater improvement in BASMI (defined as a change of at least 1 in the BASMI score) scores (-0.7 vs. -0.2, respectively; P = 0.02), and in percent change in chest expansion (44 percent vs. 19 percent, respectively, P = 0.03). Fifty-one percent of REMICADE-treated patients vs. 31 percent of pl
'"/>

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine technology :

1. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
2. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
3. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. New Study Suggests no Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon
6. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
7. Inimex Product Candidate is First Immune Defense Regulator to Cure Infections Without Causing Harmful Inflammation

Post Your Comments:

(Date:12/15/2009)... Bend Research Inc. announced,today that its clients ... an,excipient used in technologies developed by the firm to ... Bend Research clients may now reference ... regulatory filings with the FDA, Bend Research officials said. ... new development and know it will assist our,clients in ...

(Date:12/14/2009)... Dec. 14 BioTrends Research Group, Inc. ... a syndicated publication offering comprehensive insight into the ... based on a comparison of self-reported treatment approaches ... level data for over 1,000 RA patients who ... To be eligible for the audit, patients had ...

(Date:12/14/2009)... 14 Seven leading cancer ... US Oncology Research participated in ... the 2009 San Antonio Breast ... at the Henry B. Gonzalez ... Texas . Fifteen others presented ...

[0] Bend Research Clients May Now Reference Key Safety Document for Important Solubility Excipient [0] New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis [0] US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium

... Strativa,Pharmaceuticals, the proprietary products division of ... today announced that its development partner,Alfacell Corporation ... preliminary,statistical analysis of data from its confirmatory ... ONCONASE (ranpirnase), did not meet statistical,significance for ...

... Showed Clinically Meaningful Benefits for Patients with,Chemotherapy-Induced ... May 29 ,GlaxoSmithKline (GSK) today announced the ... U.S. Food and Drug Administration and new ... (casopitant), a novel,investigational NK-1 receptor antagonist. The ...

Other Medicine Technology:Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial 2 Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial 3 Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial 4 GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 2 GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 3 GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 4 GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 5 GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 6 GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 7 GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 8

Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)

(Date:12/15/2009)... CHICAGO, Dec. 15 Research shows a ... return on investment as building a culture of ... improved performance(1). According to a new white paper ... wellness solutions, the workplace represents an ideal setting ... and building and sustaining a corporate culture of ...

(Date:12/15/2009)... CHICAGO, Dec. 15 The following is being ... ,, Remarks by: Vera Rulon, MS, RHIT, CCS, ... morning, everyone and thank you joining us... ,, On ... great pleasure to introduce our next chief executive officer, ... embarked on a nationwide search for someone who we ...

(Date:12/15/2009)... midwife are generally associated with different tests and/or ... more. Women, doctors and midwives are agreed that ... sexual health, reveals a thesis from the Sahlgrenska ... Many young women see sex as a problem, ... answered questions about their sex lives, their relationships ...

(Date:12/15/2009)... Spanish scientists have found the first potential immunological clue ... by the pandemic H1N1 virus. , The study ... patients, 15 outpatients and 15 control subjects in 10 ... and August 2009. Researchers from the Hospital Clinico Universitario ... found high levels of a molecule called interleukin 17 ...

(Date:12/15/2009)... people really benefit from their looks, and in what ... Georgia and the University of Kansas found that yes; ... and therefore an increased sense of psychological well-being. This ... spend billions of dollars each year trying to become ... issue of Personal Relationships , also determines that ...

Breaking Medicine News(10 mins):Health News:Optimizing Corporate Culture is Critical to the Success of Wellness Programs 2 Health News:Dowling Press Availability Tuesday, December 15, 2009 / 10:00 a.m. CST 2 Health News:More about sex and relationships needed at gynecological visits 2 Health News:First immunological clue to why some H1N1 patients get very ill or die 2 Health News:The importance of attractiveness depends on where you live 2

[0] Optimizing Corporate Culture is Critical to the Success of Wellness Programs [0] Dowling Press Availability Tuesday, December 15, 2009 / 10:00 a.m. CST [0] More about sex and relationships needed at gynecological visits [0] First immunological clue to why some H1N1 patients get very ill or die [0] The importance of attractiveness depends on where you live

... Inc. (NYSE: ARE ) today announced the Company ... Monday, February 9, 2009, at 3:00 p.m. Eastern Time (ET), ... results for the fourth quarter and year ended December 31, ... before the market opens on Monday, February 9, 2009. , ...

... 2 Walden University,s M.S. in ... Council for Accreditation,of Counseling and Related Educational Programs ... for Higher Education,Accreditation that accredits counselor preparation master,s ... education institution that offers a,CACREP-accredited M.S. degree in ...

... the formation of fibroblasts during development also promotes their ... et al. in the February 9, 2009 issue of ... conversion of epithelial cells into fibroblast-like mesenchymal cells is ... The transcription factor Snail1 induces this conversion (known as ...

... Pharmacy Retail Level, Kidz-Med Thermofocus 5-in-1 Debuts on "Fox ... Resources (Pink Sheets: ASFX) today announced that pharmacy retail ... of 2008 compared to the 4th quarter of 2007. ... the economic recession, since implementing particular offline and online ...

... Availity, LLC, a leading health,information network, today ... of medical and behavioral health management software, ... transactions. Health care,providers with MedEZ software can ... Information Network. The partnership provides MedEZ,customers with ...

... @Heart Campaign Encourages the 44 Million Women Living with or ... Heart Health -WASHINGTON, Feb. 2 Heart disease is the ... still not receiving the same in-hospital treatment that men do ... more likely to die.(ii) In an effort to address ...

Other Medicine News:Health News:Walden University's M.S. in Mental Health Counseling Program Receives CACREP Accreditation 2 Health News:Walden University's M.S. in Mental Health Counseling Program Receives CACREP Accreditation 3 Health News:Fibroblasts invade at a snail's pace 2 Health News:Q4 2008 Sales Increase for Health and Safety Products Company 2 Health News:Q4 2008 Sales Increase for Health and Safety Products Company 3 Health News:Availity Partners With MedEZ 2 Health News:Bayer Healthcare and WomenHeart Launch Strong @Heart Campaign 2 Health News:Bayer Healthcare and WomenHeart Launch Strong @Heart Campaign 3 Health News:Bayer Healthcare and WomenHeart Launch Strong @Heart Campaign 4 Health News:Bayer Healthcare and WomenHeart Launch Strong @Heart Campaign 5

Alexandria Real Estate Equities, Inc. to Hold Its Fourth Quarter and Year End 2008 Operating and Financial Results Conference Call and Web Cast on February 9, 2009 Walden University's M.S. in Mental Health Counseling Program Receives CACREP Accreditation Fibroblasts invade at a snail's pace Q4 2008 Sales Increase for Health and Safety Products Company Availity Partners With MedEZ Bayer Healthcare and WomenHeart Launch Strong @Heart Campaign

... leader in liquid handling, we are proud ... pipette that combines simplicity, comfort and functionality ... on the results of recent independent ergonomics ... Novus gives you the power to reach ...

... The PFA-100 In Vitro Diagnostic System aids ... It is the first commercially available in ... vivo function of platelets in primary hemostasis. ... shear conditions similar to the environment of ...

... Compact is a system that measures ... samples. This rate may be relevant ... The sedimentation rate is measured in ... typically used in high-volume settings such ...

... complete range of automatic systems for performing ... mL of blood. With the introduction of ... clinical diagnostic market a truly revolutionary testing ... limitation associated with the traditional ESR techique.,By ...

Medicine Products:

Finnpipette Novus PFA-100 System StaRRsed Compact Automatic ESR Analyzer Ves-matic 20

( Findings from the ASSERT Trial Presente...)Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation,Health